Efficacy and safety of low-dose IL-2 in people with newly diagnosed type 1 diabetes (DIABIL-2): a double-blind, multicentre, randomised, placebo-controlled, phase 2b trial
Efficacy and safety of low-dose IL-2 in people with newly diagnosed type 1 diabetes (DIABIL-2): a double-blind, multicentre, randomised, placebo-controlled, phase 2b trial. // The Lancet Diabetes & Endocrinology. – URL: https://www.sciencedirect.com/science/article/pii/S2213858726001919?dgcid=rss_sd_all
Efficacy and safety of low-dose IL-2 in people with newly diagnosed type 1 diabetes (DIABIL-2): a double-blind, multicentre, randomised, placebo-controlled, phase 2b trial. The Lancet Diabetes & Endocrinology. https://www.sciencedirect.com/science/article/pii/S2213858726001919?dgcid=rss_sd_all
“Efficacy and safety of low-dose IL-2 in people with newly diagnosed type 1 diabetes (DIABIL-2): a double-blind, multicentre, randomised, placebo-controlled, phase 2b trial.” The Lancet Diabetes & Endocrinology.
@article{article68621,
title = {Efficacy and safety of low-dose IL-2 in people with newly diagnosed type 1 diabetes (DIABIL-2): a double-blind, multicentre, randomised, placebo-controlled, phase 2b trial},
journal = {The Lancet Diabetes \& Endocrinology},
url = {https://www.sciencedirect.com/science/article/pii/S2213858726001919?dgcid=rss_sd_all}
}
Abstract Background Macrophage polarisation plays a crucial role in sepsis‐associated inflammatory responses; however, the underlying molecular regulatory mechanisms remain to be further explored. Aim This study aimed to explore the...